A stock that scores a perfect 10 should be on every investor’s list of stocks to buy. Any company that receives full marks on quality, value, or growth are stocks I’d considering a perfect 10. For this article, I’m using StockRover’s stock screening tool, which screens for such qualities among a very large basket of…

The last time I wrote about Ocugen (NASDAQ:OCGN) was Nov. 3. InvestorPlace’s Larry Ramer was short OCGN stock. As of Ramer’s Nov. 8 article, he was still short.  Source: shutterstock.com/PhotobyTawat In the two weeks since Ocugen’s share price has lost 22% of its value. So I wonder if my colleague is still holding tight or…

As Black Friday approached, most investors were speculating on what the supply chain crisis would mean for the year’s biggest shopping holiday. By the time shopping began, though, most minds were on another news story. A new Covid-19 variant had been detected in South Africa and it was quickly spreading to Europe. Labeled the omicron…

News of the omicron Covid-19 variant ravished the markets last week as investors witnessed a drawdown in the S&P 500 and an uptick in the CBOE Volatility Index (VIX). To combat the new variant, Novavax (NASDAQ:NVAX) announced that it is currently developing a vaccine that would target it. In response, shares of NVAX stock have…

The smartest CEO in America today is a Greek veterinarian named Albert Bourla, CEO of Pfizer (NYSE:PFE). Source: Manuel Esteban / Shutterstock.com Bourla has made Pfizer stock a hot ticket. The stock is up 38% so far in 2021, generating $100 billion in new market capitalization. He has done this with a drug Pfizer didn’t…

When the U.S. Bureau of Labor Statistics posted October 2021 inflation climbing to 6.2%, markets fell slightly and quickly shook off the bad news. Stock markets are not a good indicator of the pressure inflation will have on goods that are demand elastic. Investors need to avoid companies that do not have a resilient brand…

Before the COVID-19 pandemic, Merck (NYSE:MRK) stock was a good one to own. The performance of Merck stock matched that of the S&P 500, and it paid a steadily rising dividend. Source: Atmosphere1 / Shutterstock.com Since then, the obsession with growth and vaccines has told a different story. Over the last two years the average…

Investors who seek a quick path to wealth will often fail. Speculators risk reacting too emotionally if a stock drops while they watch its movements like a hawk. Conversely, investors who search for stocks to buy and hold for the very long term will have more patience. Taking the time to research a company’s prospects…

Ocugen (NASDAQ:OCGN) is a stock that I continue to be wrong about. Over the past month, OCGN stock has gained more than 80%, greatly testing my patience. The stock has fallen from the $17 mark it reached this morning, but is still higher than I expected last month. Source: shutterstock.com/PhotobyTawat In my last article about…

Novavax’s (NASDAQ:NVAX) stock price had fallen more than 45% in the last month having disappointed investors. It has taken some of that ground back, now down only 24% for the month, and could still be a promising buy. Source: Ascannio/Shutterstock.com The stock plunged because of the company’s delay in filing for an Emergency Use Authorization…

Investors in the vaccine maker Novavax (NASDAQ:NVAX) stock witnessed rollercoaster trading in September and October. Source: Ascannio/Shutterstock.com NVAX stock ended August shy of $240. By Sept. 8, the shares approached $280. Yet now, they are hovering just below $150. In other words, the record high of $331.68 seen in early February is now in the…

Like most of the other companies that jumped into the COVID vaccine competition, Novavax (NASDAQ:NVAX) stock tells the story of the Great Vaccine Race. Since the Feb. 25, 2020, NVAX stock has been on a roller coaster ride that’s lifted the value by more than 1,772%. Source: Ascannio/Shutterstock.com That’s not just a random date, but…

The vaccine race is still experiencing many twists and turns, but one company is nearing a key milestone. This news comes just a week after the company experienced a significant setback, though. Maryland-based Novavax (NASDAQ:NVAX) has announced that it is taking steps toward gaining authorization to administer its experimental Covid-19 vaccine in the United Kingdom.…

Income investors are facing negative real returns as inflation rates soar. Not only is wage growth falling behind inflation, but cash savings are earning almost nothing in bank accounts. Investors who waited years for interest rates to rise and pay a better return now cannot wait. However, those who found high-yield stock gems have earned…

Given all the talk surrounding the novel coronavirus and its multiple variants, it’s quite clear that Americans are suffering not only from the global health crisis but also from pandemic fatigue. As the concept of retail revenge demonstrates, people don’t want to live in fear anymore. Nevertheless, what may be a permanent impact of Covid-19…

Despite delays in obtaining approval for its Covid-19 vaccine, Novavax (NASDAQ:NVAX) has a competitive edge compared to its peers. The company has its production partners ready to ship its vaccine. It also initiated a clinical trial for evaluating a combination of Covid and seasonal influenza vaccines. Still, NVAX stock is poised to trade higher in…

In 2020, the race for the Covid-19 vaccine distorted investment inflows in the biotechnology sector. Back then, emerging biotech stocks tripled or more on hopes that they would come out with a vaccine. Buying interest in vaccine research resumed earlier this year when Covid variants emerged. Once again, markets did not learn their lesson from…

In this kind of market it’s hard to tell where we’re headed. That’s why sticking with the best large-cap stocks is the best idea for now. Is the economy too hot or is it cooling due to the delta variant? Is there too much money in the system or is there still too much economic…